PTX-100 is under clinical development by Prescient Therapeutics and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData, Phase I drugs for Peripheral T-Cell Lymphomas (PTCL) have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PTX-100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PTX-100 overview

PTX-100 (GGTI-2418) is under development for the treatment of angioimmunoblastic T-cell lymphoma (AITL), cutaneous T cell lymphoma, peripheral T-cell lymphoma,  gastric cancer, solid tumours including multiple myeloma, pancreatic cancer and colorectal cancer. It is administered by intravenous route. The drug candidate is synthetic peptidomimetic which acts by targeting geranylgeranyltransferase I (GGTase I) and transforming protein RhoA. It was under development for the treatment of adult T-cell leukemia and lymphoma (ATL), Burkitt lymphoma, diffuse large B-cell lymphoma (DLBCL), metastatic breast cancer and lung cancer.

Prescient Therapeutics overview

Prescient Therapeutics, formerly Virax, is a biotechnology company. It develops novel medicines for cancer treatment. The company is investigating OmniCAR, an immune receptor platform that controls T-cell activity and multi-antigen targeting with a single cell product for combined approach to formulate novel chimeric antigen receptor T (CAR-T) to treat cancer and other diseases. Its pipeline products include PTX-100, a compound which blocks geranylgeranyl transferase-1 (GGT-1), a cancer growth enzyme; and PTX-200, a novel PH domain inhibitor that obstructs protein kinase B or AKT signalling, which develops breast, ovarian cancer and leukemia. The company’s OmniCAR platform is built on technology licensed from University of Pennsylvania and SpyTag/SpyCatcher binding system licensed from Oxford University to develop improved CAR-T approaches for treating cancer and solid tumors. Prescient Therapeutics is headquartered in South Melbourne, Victoria, Australia.

For a complete picture of PTX-100’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.